NINJ1: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: NINJ1

NCBI ID: G4814

NINJ1

NINJ1: A Protein Target for Cancer and Neurodegenerative Diseases

NINJ1 (Ninjectin-1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscle. It is a member of theulin family, which includes a variety of proteins that are involved in the regulation of cell signaling pathways. One of the unique features of NINJ1 is its ability to interact with several different signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. This makes it an attractive target for drug development, as it has been shown to be involved in a wide range of physiological processes, including cell growth, differentiation, and survival.

The TGF-β pathway is a key regulator of cell signaling pathways, and is involved in the regulation of cell proliferation, differentiation, and survival. This pathway is activated by the binding of the protein TGF-β1 to its receptor, which is found on the surface of many different cell types. Once bound, TGF-β1 can activate the downstream targets of the pathway, including the Smad gene, which is involved in the regulation of cell signaling pathways.

The PI3K/Akt pathway is a signaling pathway that is involved in the regulation of cell survival and proliferation. This pathway is activated by the binding of the protein PI3K to its receptor, which is found on the surface of many different cell types. Once bound, PI3K can activate the downstream target, Akt, which is involved in the regulation of cell signaling pathways.

NINJ1 has been shown to be involved in the regulation of TGF-β and PI3K/Akt signaling pathways. It has been shown to interact with the TGF-β receptor and the PI3K/Akt receptor, and to play a role in the regulation of cell signaling pathways. This suggests that NINJ1 may be a useful drug target for the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its involvement in the TGF-β and PI3K/Akt signaling pathways, NINJ1 has also been shown to be involved in the regulation of a wide range of other cellular processes. For example, it has been shown to be involved in the regulation of cell adhesion, cell migration, and the regulation of the cytoskeleton. This suggests that NINJ1 may be a useful drug target for the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Given its involvement in multiple signaling pathways, NINJ1 is an attractive target for drug development. Researchers are currently working to identify small molecules that can inhibit the activity of NINJ1, and to determine the mechanism of action of these compounds. This work is being done in order to develop new treatments for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, NINJ1 is a protein that is expressed in various tissues throughout the body, and is involved in the regulation of multiple signaling pathways. Its ability to interact with several different signaling pathways makes it an attractive target for drug development, and its involvement in the regulation of a wide range of cellular processes makes it a potential therapeutic target for the treatment of a wide range of diseases. Further research is needed to understand the mechanism of action of NINJ1 and to develop new treatments for cancer, neurodegenerative diseases, and autoimmune diseases.

Protein Name: Ninjurin 1

Functions: Homophilic transmembrane adhesion molecule involved in various processes such as inflammation, cell death, axonal growth, cell chemotaxis and angiogenesis (PubMed:8780658, PubMed:9261151, PubMed:33472215). Promotes cell adhesion by mediating homophilic interactions via its extracellular N-terminal adhesion motif (N-NAM) (PubMed:33028854). Involved in the progression of the inflammatory stress by promoting cell-to-cell interactions between immune cells and endothelial cells (PubMed:22162058, PubMed:26677008, PubMed:32147432). Involved in leukocyte migration during inflammation by promoting transendothelial migration of macrophages via homotypic binding (By similarity). Promotes the migration of monocytes across the brain endothelium to central nervous system inflammatory lesions (PubMed:22162058). Acts as a regulator of Toll-like receptor 4 (TLR4) signaling triggered by lipopolysaccharide (LPS) during systemic inflammation; directly binds LPS (PubMed:26677008). Acts as a mediator of both programmed and necrotic cell death (PubMed:33472215). Plays a key role in the induction of plasma membrane rupture during programmed and necrotic cell death: oligomerizes in response to death stimuli to mediate plasma membrane rupture (cytolysis), leading to release intracellular molecules named damage-associated molecular patterns (DAMPs) that propagate the inflammatory response (PubMed:33472215). Plays a role in nerve regeneration by promoting maturation of Schwann cells (PubMed:8780658, PubMed:9261151). Acts as a regulator of angiogenesis (PubMed:33028854). Promotes the formation of new vessels by mediating the interaction between capillary pericyte cells and endothelial cells (By similarity). Promotes osteoclasts development by enhancing the survival of prefusion osteoclasts (By similarity). Also involved in striated muscle growth and differentiation (By similarity)

The "NINJ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NINJ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets